Skip to main content
Search
Main content
Nature communications
Published

Plasma eMTBR-tau243 and p-tau205 as T2 biomarkers for biological staging and prognosis in Alzheimer's disease

Authors

Sohyun Yim, Eun Hye Lee, Jungah Lee, Daeun Shin, Heekyoung Kang, Hee Kyung Park, Seonghyeon Kim, Joel B Braunstein, Philip B Verghese, Tim West, Matthew R Meyer, Theresa A Day, Henrik Zetterberg, Fernando Gonzalez-Ortiz, Nicholas J Ashton, Tobias Bittner, Annunziata Di Domenico, Gwendlyn Kollmorgen, Hyemin Jang, Jihwan Yun, Min Young Chun, Duk L Na, Hee Jin Kim, Yuna Gu, Jun Pyo Kim, Sang Won Seo

Abstract

Nat Commun. 2026 Oct 19;17(1):11770. doi: 10.1038/s41467-026-78582-x.

ABSTRACT

Plasma biomarkers that reflect distinct stages of Alzheimer's disease (AD) could enable scalable biological staging. We evaluated phosphorylated tau (p-tau) species across multiple analytical platforms and the endogenously cleaved microtubule-binding region containing residue 243 (eMTBR-tau243) using a dedicated LC-MS/MS platform in a well-characterized cohort with amyloid PET and a subset with tau PET. While T1 biomarkers increased during preclinical stages, eMTBR-tau243 and p-tau205 increased later, consistent with fibrillar tau aggregation. eMTBR-tau243 showed the strongest and stage-dependent associations with regional tau PET and cognition, outperforming T1 biomarkers in predicting cross-sectional and longitudinal cognition. A plasma-based tau staging system integrating p-tau217 and eMTBR-tau243 closely aligned with PET-based tau staging and predicted longitudinal cognitive trajectories. These findings support plasma eMTBR-tau243 as a prototypical T2 biomarker and highlight the potential of plasma-based tau staging for prognosis and therapeutic decision-making in AD.

PMID:43052277 | DOI:10.1038/s41467-026-78582-x

UK DRI Authors

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg